Cargando…

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Martina, Catalano, Winchler, Costanza, De Gennaro Aquino, Irene, Papa, Francesca, Buttitta, Eleonora, Rossi, Gemma, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/
https://www.ncbi.nlm.nih.gov/pubmed/36109437
http://dx.doi.org/10.1007/s12029-022-00865-5
_version_ 1785128761284362240
author Roviello, Giandomenico
Martina, Catalano
Winchler, Costanza
De Gennaro Aquino, Irene
Papa, Francesca
Buttitta, Eleonora
Rossi, Gemma
Antonuzzo, Lorenzo
author_facet Roviello, Giandomenico
Martina, Catalano
Winchler, Costanza
De Gennaro Aquino, Irene
Papa, Francesca
Buttitta, Eleonora
Rossi, Gemma
Antonuzzo, Lorenzo
author_sort Roviello, Giandomenico
collection PubMed
description BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with paclitaxel has proved to be a safe and active option for second-line treatment in GC patients. MATERIAL AND METHODS: Advanced GC patients who received a 28-day cycles of ramucirumab and paclitaxel until disease progression or unacceptable toxicity were evaluated. Eligible patients had ECOG PS ≤ 1 and adequate organ function. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method and Cox proportional-hazards regression models were used for survival analyses. RESULTS: In our single institution experience, we included a total of 67 patients. A median OS of 8 months and a median PFS of 4 months, were recorded. In patients experiencing an initial partial response (PR), we observed a significant association between tumor response and survival outcomes (OS and PFS). The OS and PFS were 15 and 11 months in patients who experienced PR compared to 8 and 4 months in patients without PR (p = 0.02; p = 0.04). CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest overall response rate reported to date for patients with previously treated advanced GC. In our experience, the initial tumor response is associated with a greater survival benefit which could be further improved by the identification of biomarkers predicting response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12029-022-00865-5.
format Online
Article
Text
id pubmed-10613139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-106131392023-10-30 Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy Roviello, Giandomenico Martina, Catalano Winchler, Costanza De Gennaro Aquino, Irene Papa, Francesca Buttitta, Eleonora Rossi, Gemma Antonuzzo, Lorenzo J Gastrointest Cancer Original Research BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with paclitaxel has proved to be a safe and active option for second-line treatment in GC patients. MATERIAL AND METHODS: Advanced GC patients who received a 28-day cycles of ramucirumab and paclitaxel until disease progression or unacceptable toxicity were evaluated. Eligible patients had ECOG PS ≤ 1 and adequate organ function. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method and Cox proportional-hazards regression models were used for survival analyses. RESULTS: In our single institution experience, we included a total of 67 patients. A median OS of 8 months and a median PFS of 4 months, were recorded. In patients experiencing an initial partial response (PR), we observed a significant association between tumor response and survival outcomes (OS and PFS). The OS and PFS were 15 and 11 months in patients who experienced PR compared to 8 and 4 months in patients without PR (p = 0.02; p = 0.04). CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest overall response rate reported to date for patients with previously treated advanced GC. In our experience, the initial tumor response is associated with a greater survival benefit which could be further improved by the identification of biomarkers predicting response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12029-022-00865-5. Springer US 2022-09-15 2023 /pmc/articles/PMC10613139/ /pubmed/36109437 http://dx.doi.org/10.1007/s12029-022-00865-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Roviello, Giandomenico
Martina, Catalano
Winchler, Costanza
De Gennaro Aquino, Irene
Papa, Francesca
Buttitta, Eleonora
Rossi, Gemma
Antonuzzo, Lorenzo
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title_full Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title_fullStr Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title_full_unstemmed Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title_short Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
title_sort correlation between tumor response and survival outcomes in patients with advanced gastric cancer receiving ramucirumab and paclitaxel as second-line therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/
https://www.ncbi.nlm.nih.gov/pubmed/36109437
http://dx.doi.org/10.1007/s12029-022-00865-5
work_keys_str_mv AT roviellogiandomenico correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT martinacatalano correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT winchlercostanza correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT degennaroaquinoirene correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT papafrancesca correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT buttittaeleonora correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT rossigemma correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy
AT antonuzzolorenzo correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy